Allogene Therapeutics, Inc. (ALLO)
2.035
-0.06
(-2.63%)
USD |
NASDAQ |
Aug 24, 16:00
2.03
0.00 (0.00%)
After-Hours: 20:00
Allogene Therapeutics Total Liabilities (Quarterly) : 113.92M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 113.92M |
| March 31, 2026 | 117.08M |
| December 31, 2025 | 123.36M |
| September 30, 2025 | 124.44M |
| June 30, 2025 | 126.03M |
| March 31, 2025 | 122.59M |
| December 31, 2024 | 126.53M |
| September 30, 2024 | 125.37M |
| June 30, 2024 | 131.84M |
| March 31, 2024 | 124.98M |
| December 31, 2023 | 130.60M |
| September 30, 2023 | 129.22M |
| June 30, 2023 | 148.06M |
| March 31, 2023 | 154.61M |
| December 31, 2022 | 151.21M |
| September 30, 2022 | 147.61M |
| June 30, 2022 | 145.70M |
| March 31, 2022 | 109.40M |
| Date | Value |
|---|---|
| December 31, 2021 | 125.63M |
| September 30, 2021 | 109.30M |
| June 30, 2021 | 102.91M |
| March 31, 2021 | 109.26M |
| December 31, 2020 | 148.21M |
| September 30, 2020 | 103.77M |
| June 30, 2020 | 95.12M |
| March 31, 2020 | 82.00M |
| December 31, 2019 | 88.78M |
| September 30, 2019 | 75.83M |
| June 30, 2019 | 78.36M |
| March 31, 2019 | 68.14M |
| December 31, 2018 | 70.69M |
| September 30, 2018 | 192.63M |
| June 30, 2018 | 17.23M |
| March 31, 2018 | |
| December 31, 2017 | 0.002M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Cartesian Therapeutics, Inc. | 443.85M |
| Beam Therapeutics, Inc. | 318.91M |
| Kyverna Therapeutics, Inc. | 54.27M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 550.09M |
| Shareholders Equity (Quarterly) | 436.18M |
| Debt to Equity Ratio | 0.1811 |
| Current Ratio | 10.72 |
| Net Debt Paydown Yield | 0.28% |